Table 1.
Patient characteristics
| Characteristic | No. patients (%) |
|---|---|
| Age at diagnosis, median (y), range | 33 (11-80) |
| Primary tumor | |
| Paraganglioma | 26 (63) |
| Pheochromocytoma | 15 (37) |
| Sex | |
| Female | 24 (58) |
| Male | 17 (42) |
| Disease extent at initial presentation | |
| Localized | 23 (56) |
| Metastatic | 18 (44) |
| Germline mutation | |
| None | 28 (68) |
| SDHB | 12 (29) |
| SDHD | 1 (2) |
| Prior local therapiesa | |
| Surgical resection | 37 (90) |
| Radiofrequency ablation | 6 (15) |
| Cryoablation | 1 (2) |
| Ethanol ablation | 1 (2) |
| Prior medical therapiesa | |
| CVD | 8 (20) |
| Octreotide | 5 (12) |
| Zoledronic acid | 4 (10) |
| Denosumab | 4 (10) |
| 131I-MIBG | 3 (7) |
| Pazopanib | 3 (7) |
| Other | 5 (12) |
| Primary indication for EBRT | |
| Local control | 27 (66) |
| Pain | 9 (22) |
| Spinal cord compression | 5 (12) |
CVD, cyclophosphamide, vincristine, dacarbazine; EBRT, external beam radiation therapy; 131I-MIBG, 131I-metaiodobenzylguanidine.
a
Some patients received multiple prior treatments.